Standigm ASK
AI-powered drug discovery platform for novel target identification and drug candidate generation
Platform · Cloud SaaSCompany source
Company profile
About Standigm
Standigm is a biotechnology company specializing in artificial intelligence-powered drug discovery and development. Founded to address the inefficiencies and high costs of traditional drug discovery, Standigm has developed proprietary AI platforms that integrate deep learning, machine learning, and biological knowledge to identify novel drug candidates, predict drug efficacy, and discover new therapeutic targets. The company's technology analyzes vast amounts of biomedical data including genomics, proteomics, and chemical structures to uncover hidden relationships between diseases, targets, and compounds. Standigm serves pharmaceutical companies, biotechnology firms, and academic research institutions seeking to accelerate their drug discovery pipelines and reduce development costs. The platform has demonstrated capabilities across multiple therapeutic areas including oncology, metabolic diseases, and rare diseases. By combining computational predictions with experimental validation, Standigm aims to increase the success rate of drug development while significantly reducing the time and cost required to bring new therapeutics to market. The company represents a new generation of AI-native biotech firms transforming how medicines are discovered and developed.
Company description Standigm official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Standigm?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- metabolic diseases
- oncology
- rare diseases
Who it serves
- Academic research institutions
- Biotechnology firms
- Pharma
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Systematic discovery of disease-modifying targets by prediction from knowledge graph-based AI model and experimental validation: Parkinson's disease case.Computational and structural biotechnology journal · Jan 1, 2026
Quantum-Informed Molecular Representation Learning Enhancing ADMET Property Prediction.Journal of chemical information and modeling · Jul 8, 2024
Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation: Implications in Parkinson's disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · May 1, 2024
Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson's disease.Journal of neuroinflammation · Feb 21, 2024
Selenium reduction of ubiquinone via SQOR suppresses ferroptosis.Nature metabolism · Feb 1, 2024
Standigm ASK™: knowledge graph and artificial intelligence platform applied to target discovery in idiopathic pulmonary fibrosis.Briefings in bioinformatics · Jan 22, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Standigm
Recent articles published on Standigm's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.